Keywords: sepracor, 4th-qtr, xopenex, revenues, leap, firm, reported
Sepracor's 4th-qtr Xopenex revenues leap 53%
Article | 26 January 2004
US firm Sepracor has reported that, for the three months ended December 31, 2003, its consolidated turnover was approximately $112.3 million, a rise ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
